Fabrication of Porous Fe-Based Metal–Organic Complex for the Enhanced Delivery of 5-Fluorouracil in In Vitro Treatment of Cancer Cells

Abstract

Metal–organic complexes are one of the most studied materials in the last few decades, which are fabricated from organic ligands and metal ions to form robust frameworks with porous structures. In this work, iron-1,4-benzenedicarboxylic-polyethylene glycol (Fe-BDC-PEG) with a porous structure was successfully constructed by an iron(III) benzene dicarboxylate and polyethylene glycol diacid. The drug-delivery properties of the resultant Fe-BDC-PEG were tested for the loading and release of the 5-fluorouracil compound. The maximal loading capacity of Fe-BDC-PEG for 5-fluorouracil was determined to be 348.22 mg/g. The drug release of 5-fluorouracil-loaded Fe-BDC-PEG after 7 days was 92.69% and reached a maximum of 97.52% after 10 days. The 7 day and acute oral toxicity of Fe-BDC-PEG in mice were studied. The results show that no reasonable change or mortality was observed upon administration of Fe-BDC-PEG complex in mice at 10 g/kg body weight. When the uptake of Fe-BDC-PEG particles in mice was continued for 7 consecutive days, the mortality, feed consumption, body weight, and daily activity were negligibly changed.

MOFs for next-generation cancer therapeutics through a biophysical approach—a review

“…The drug release rate from the loaded material increased dramatically on day one. Following 7 days in the solution, approximately 92.69% of the drug was released from the material, and after 10 days, 97.52% of 5-FU had been released from the loaded Fe-BDC-PEG complex (Le et al, 2022). In animal models, pharmacokinetic studies have been used to assess the Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) of MOFs.…”

“…MOF has been shown to be a stable and safe platform for the development of extremely effective DDS for cancer therapy ( Lei et al, 2018 ; Li Y. et al, 2020 ). Encapsulation within MOFs has no limits to drug delivery; it is also being considered for use in the therapy of various types of cancer ( Hartlieb et al, 2017 ) which include breast, gastric, and colon ( Le et al, 2022 ). The drug delivery mechanism of MOFs allows for a manageable and slow release of drugs, which is a significant advantage over other DDS.…”

“…The drug release rate from the loaded material increased dramatically on day one. Following 7 days in the solution, approximately 92.69% of the drug was released from the material, and after 10 days, 97.52% of 5-FU had been released from the loaded Fe-BDC-PEG complex ( Le et al, 2022 ).…”

Fabrication of Red Blood Cell-Mimicking Janus Microparticles with Enhanced Upconversion Luminescence and Drug Delivery Performance Using Double-Needle Electrospray

“…The method of loading drugs into particles is another key aspect of drug delivery systems. Conventional drug delivery systems often have the disadvantage of initial drug burst of release, leading to a massive premature loss of drugs. , Strategies including multilayer embedding and environmental responses, such as pH and ROS, − have been proposed to mitigate this issue, but they often require complex manufacturing procedures. , In drug delivery systems, Fe 3 O 4 MNPs can serve as the direct carriers, reducing burst drug release and improving the drug utilization rate. , Additionally, according to the previous studies, − the drug carrier with porous structure exhibits a larger surface area and enables an increase in the drug loading capacity and a controlled release of the drug. Therefore, loading drugs into porous Fe 3 O 4 MNPs might be a more convenient alternative compared to the complex covalent combinations of drugs on MNPs.…”

Table1.docx

“…MOF has been shown to be a stable and safe platform for the development of extremely effective DDS for cancer therapy (Lei et al, 2018;Li Y. et al, 2020). Encapsulation within MOFs has no limits to drug delivery; it is also being considered for use in the therapy of various types of cancer (Hartlieb et al, 2017) which include breast, gastric, and colon (Le et al, 2022). The drug delivery mechanism of MOFs allows for a manageable and slow release of drugs, which is a significant advantage over other DDS.…”